Dr. Mitchell

Edith P. Mitchell, MD, FACP

Contact Dr. Mitchell

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 955-8874
(215) 503-9506 fax

Most Recent Peer-reviewed Publications

  1. American Society of Clinical Oncology strategic plan for increasing racial and ethnic diversity in the oncology workforce
  2. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer
  3. Cetuximab plus chemoradiotherapy in immunocompetent patients with anal carcinoma: A phase II Eastern cooperative oncology group-American college of radiology imaging network cancer research group trial (E3205)
  4. How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials
  5. Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms
  6. African American Patients’ Psychosocial Support Needs and Barriers to Treatment: Patient Needs Assessment
  7. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study
  8. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy
  9. Moonshot Toward a Cure for Cancer
  10. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism
  11. Positive association of fibroadenomatoid change with HER2-negative invasive breast cancer: A co-occurrence study
  12. 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: A randomized Phase IIb study
  13. Efficacy endpoints of radiation therapy group protocol 0247: A randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer
  14. Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer
  15. Determinants of pain severity changes in ambulatory patients with cancer: An analysis from eastern cooperative oncology group trial E2Z02
  16. Determining efficacy of breast cancer therapy by PET imaging of HER2 mRNA
  17. Consistent Surgeon Evaluations of Three-Dimensional Rendering of PET/CT Scans of the Abdomen of a Patient with a Ductal Pancreatic Mass
  18. Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer
  19. A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer
  20. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer